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Summary: The efficacy and safety of gabapentin as mono- 
therapy for treatment of partial onset seizures were evaluated in 
three large multicenter, double-blind, parallel-group, dose- 
controlled trials. In the first trial, 275 outpatients with refrac- 
tory partial epilepsy maintained on stable doses of one or two 
antiepileptic drugs (AEDs) were switched to gabapentin (GBP) 
monotherapy at 600 mg, 1200 mg, or 2400 mg daily. Patients 
were required to exit the 26-week double-blind phase of the 
study if they experienced worsening of seizure frequency. With 
respect to time to exit, there was no statistically significant 
difference among the three groups; only 3% of patients with- 
drew from the trial because of adverse events. In the second 
study, 82 hospitalized patients with medically refractory epi- 
lepsy were tapered off baseline AEDs and randomly assigned 
to GBP monotherapy at 300 mg/day or 3600 mg/day. Patients 
remained in the trial for a maximum of 8 days but had to exit 
the trial if they experienced one or more exit events. Time to 
exit was significantly longer in patients in the 3600-mg group 
(151 h) compared with those in the 300-mg group (85 h) (p = 
0.0001). None of the patients withdrew from the trial because 
of side effects. In the third study, 292 patients with newly 
diagnosed partial seizures were randomized to GBP 300, 900, 
or 1800 mg/day or to carbamazepine (CBZ) 600 mg/day. Pa- 
tients remained in the trial for up to 6 months or until they 
experienced an exit event. Mean time to exit was significantly 
longer for patients who received GBP 900 mg/day (p = 0.02) 
or 1800 mg/day 0, = 0.04) compared with those who received 
300 mg/day. The completion rate for the CBZ group (37%) was 
similar to that of the GBP 900-mg (39%) and 1800-mg (38%) 
groups. Patients receiving CBZ had a higher withdrawal rate 
because of adverse events compared with the GBP 900-mg and 
1800-mg groups. The results of these trials provide good evi- 
dence of the efficacy and safety of GBP as monotherapy for the 
treatment of partial-onset seizures. Key words: Gabapentin- 
Monotherapy-Newly diagnosed seizures-Partial-onset sei- 
zures-Refractory epilepsy. 
Gabapentin (GBP) is approved as adjunctive therapy 
for the treatment of partial-onset seizures in patients a1 
least 12 years of age, based on the results of three large. 
multicenter, double-blind, placebo-controlled, dose- 
ranging, parallel-group clinical trials (1-3). In all three 
studies, patients randomized to GBP at daily doses be- 
tween 600 and 1800 mg had a statistically significant 
reduction in seizures compared with placebo-treated pa- 
tients. More recently, the safety and efficacy of GBP as 
monotherapy were evaluated in three clinical trials in 
adult patients with refractory and newly diagnosed par- 
tial epilepsy as well as in children with newly diagnosed 
partial epilepsy of childhood with centrotemporal sharp 
waves (rolandic epilepsy). The pediatric trial is reviewed 
elsewhere in this supplement. 
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OUTPATIENT CLINICAL TRIAL IN PATIENTS 
WITH REFRACTORY PARTIAL EPILEPSY 
This was a multicenter, randomized, double-blind, 
dose-response clinical trial performed on patients with 
refractory pzrtial epilepsy (4). The study consisted of an 
8-week baseline phase followed by a 26-week double- 
blind phase. Eligible patients were 12 years or older, 
with at least four complex partial or secondarily gener- 
alized seizures during the baseline phase while main- 
tained on stable doses of one or two antiepileptic drugs 
(AEDs). After the baseline phase, qualifying patients 
were randomized to receive GBP at daily doses of 600 
mg, 1200 mg, or 2400 mg taken on a tid schedule. To 
maintain their safety, patients were required to exit the 
study if they experienced protocol-defined worsening of 
seizure frequency during the double-blind phase. A total 
of 275 patients were randomized in this trial, with no 
statistically significant difference in time to exit, the pri- 
mary efficacy variable, among the three dosage groups. 
GBP was very well tolerated in this trial, with only 3% of 
patients exiting because of adverse events. The most 
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FIG. 1. Kaplan-Meier estimate of time to exit. Patients in the 
3600-mg/d gabapentin dosage group remained in the study sig- 
nificantly longer than the patients in the 300-mg/d gabapentin 
group (p = 0.0001, generalized Wilcoxon's test). From Bergey et 
al. (7). 
common adverse events, dizziness and somnolence, were 
transient in the majority of patients. 
The results of this trial were uninformative (5) because 
of the lack of a significant dose-response relationship. 
This may have been due to the trial design, the refractory 
nature of the patient population studied, the occurrence 
of withdrawal seizures, and the limited range of GBP 
dosages compared. Results from the open-label phase of 
this trial that allowed titration of GBP up to 4800 mg/day 
suggested that higher GBP dosages are effective as 
monotherapy in a subgroup of patients with refractory 
partial epilepsy (6). 
INPATIENT CLINICAL TRIAL IN 
HOSPITALIZED PATIENTS WITH 
REFRACTORY PARTIAL EPILEPSY 
In this double-blind trial, patients at least 12 years of 
age with refractory partial epilepsy admitted for CCTV- 
EEG monitoring as part of their presurgical work-up for 
epilepsy were randomized to GBP monotherapy at 300 
mg/day or 3600 mg/day (7). The full dose of GBP was 
administered on day 1 in three equally divided doses 
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FIG. 2. Mean gabapentin plasma concentrations at trough were 
about sevenfold higher for the 3600-mgld dosage group than for 
the 300-mg/d dosage group. From Bergey et al. (7). 
every 8 h. Patients remained in the trial for a maximum 
of 8 days but had to exit the trial if they experienced a 
total of four complex partial or secondarily generalized 
seizures, a single generalized tonic-clonic seizure if none 
was previously experienced, status epilepticus, or a clini- 
cally significant intensification in seizure duration or se- 
verity. A total of 82 patients were randomized in this 
trial, with time to exit, the primary efficacy variable, 
being significantly longer in patients randomized to the 
high dosage group (mean time 151 h) compared with the 
low dosage group (mean time 85 h) (p = 0.0001) (Fig. 
1). The results of the secondary efficacy variable, per- 
centage of patients who completed the trial, were con- 
sistent with the primary outcome data. A total of 53% of 
patients in the 3600-mg/day group completed the trial 
compared with 17% of those in the 300-mg/day group (p 
= 0.002). Trough GBP serum levels averaged 9 mg/L in, 
the 3600-mg/day group and 1 mgL in the 300-mglday 
group (Fig. 2). Despite rapid administration of full-dose 
GBP at 3600 mg/day, none of the patients exited the trial 
because of side effects. The most common adverse 
events in the 3600-mg/day group were dizziness, ataxia, 
and somnolence (Table 1). 
This trial demonstrated the short-term anticonvulsant 
properties of GBP as monotherapy and showed that this 
drug can be safely initiated at 3600 mg/day if needed, at 
least in an inpatient setting. 
OUTPATIENT CLINICAL TRIAL IN PATIENTS 
WITH NEWLY DIAGNOSED 
PARTIAL SEIZURES 
This was a multicenter, double-blind, dose-controlled 
clinical trial designed to evaluate the safety and efficacy 
of GBP as monotherapy for patients with newly diag- 
nosed partial epilepsy (8). Eligible patients were 12 years 
or older with a history of at least two unprovoked partial 
seizures, with or without secondary generalization, in the 
TABLE 1. Most commonly occurring adverse events [no. 
(%) of patients]" 
Gabapentin dosage 
300 mg/d 3600 mg/d 
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a Adverse events experienced by more than three patients. 
Adapted from Bergey et al. (7). 
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TABLE 2. Completion, exit, and adverse event withdrawal rates" 
Gabapentin (mg/d) Carbamazepine (600 mg/d) 
300 (n = 72) 900 (n = 72) 1800 (n = 74) (n = 74) 
Completion rate 18 (25.0) 28 (38.9) 28 (37.8) 
Exit rate 45 (62.5) 29 (40.3) 32 (43.2) 
Exit + AE withdrawal rate 45 (62.5) 32 (44.4) 42 (56.8) 




40 (54.1 ) 
AE, adverse event. 
a Values are number (%) of patients. 
From Chadwick et al. (8). 
previous 6 months. Qualifying patients were randomized 
in a double-blind fashion to GBP at 300 mg/day, 900 
mg/day, or 1800 mg/day. There was also a comparative 
group who received CBZ at 600 mg/day in an open-label 
fashion. Patients remained in the trial for up to 6 months 
but had to exit if they experienced a single secondarily 
generalized seizure or three partial seizures. A total of 
292 patients were randomized in this trial, with 72-74 
patients in each treatment group. Time to exit was sig- 
nificantly longer for patients who received GBP 900 mg/ 
day or 1800 mg/day compared with those who received 
300 mg/day (p = 0.02 and 0.04, respectively). Although 
the CBZ group could not be included in the statistical 
analysis, the completion rate for patients in that group 
(37%) was similar to that of the GBP 900-mg (39%) and 
1800-mg (38%) groups (Table 2). Overall, patients who 
received CBZ had a lower exit rate but a higher rate of 
withdrawal due to adverse events, compared with the 
GBP 900-mg and 1800-mg groups (Table 2 ) .  The most 
common adverse events experienced by GBP-treated pa- 
tients were dizziness, headache, and fatigue (Table 3). 
In this trial, a significant dose-response relationship 
was demonstrated, providing evidence for the efficacy of 
GBP monotherapy in patients with newly diagnosed par- 
tial epilepsy. It also suggested that an appropriate starting 
dose in this patient population is 900 mg/day. As with 
other AEDs, the dose should be gradually titrated to ef- 
ficacy or tolerability in case of seizure recurrence. 
CONCLUSIONS 
On the basis of the results of the aforementioned trials, 
there is now growing evidence to support the efficacy of 
GBP as monotherapy for the treatment of partial-onset 
seizures. The exit task is to define specific patient popu- 
lations with partial epilepsy in whom the pharmacoki- 
netic and/or safety profile of GBP would make it an 
attractive choice as monotherapy. Some of those popu- 
lations include patients with porphyria, hepatic disease, 
elderly patients receiving polytherapy, children with be- 
nign partial epilepsies of childhood, and patients receiv- 
ing immunosuppressants. For example, there is now evi- 
dence, derived from cell cultures and clinical reports, 
that GBP does not increase porphyrin production in pa- 
tients with porphyrias, making it a first-line agent for the 
treatment of seizures in these disorders. In addition, GBP 
is the only AED, except for vigabatrin, that is not he- 
patically metabolized, and it would therefore be very 
useful as monotherapy for patients with seizures and 
liver disease. Seizures in the elderly are usually easily 
controlled, but patients in this age group are much more 
sensitive to the adverse events of AEDs. Elderly patients 
TABLE 3. Adverse events occurring in at least jive gabapentin-treated patients 
Gabapentin (mg/d) Carbamazepine (600 mg/d) 
Adverse event 300 (n = 72) 900 (n = 72) 
Dizziness 5 11 
Headache 10 10 
Fatigue 9 9 
Nausea or vomiting 4 5 
Somnolence 2 5 
Viral infection 1 5 
Abdominal pain 3 3 
Nervousness 1 3 
Weight increase 4 2 
Increased appetite 0 4 
Rhinitis 2 4 
Bronchitis 2 2 
Paresthesia 2 2 
Pharyngitis 1 1 






























From Chadwick et al. (8). 
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also tend to be receiving a number of prescription medi- 
cations, many of which are metabolized in the liver (9- 
11) and can lead to significant drug-drug interactions in 
the presence of AEDs that have a propensity to induce or 
inhibit hepatic microsomal enzymes. The safety of GBP 
and its lack of drug-drug interactions make it a very 
attractive choice in this patient population. Its lack of 
drug-drug interaction is also an advantage in patients 
with partial seizures who are receiving concurrent treat- 
ment with immunosuppressive drugs. 
What is now needed are comparative randomized 
clinical trials between GBP and the standard AEDs for 
patients with newly diagnosed partial epilepsy, to evalu- 
ate the relative safety and efficacy of this AED. In ad- 
dition, clinical trials in specific patient populations with 
partial epilepsy would be very helpful in better defining 
the role of this AED as monotherapy. 
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